SEC Comment Letter 0000000000-25-002149 to Anebulo Pharmaceuticals, Inc. (ANEB) (CIK 0001815974) (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB) (CIK 0001815974)
Date: Feb. 25, 2025 · CIK: 0001815974 · Accession: 0000000000-25-002149
AI Filing Summary & Sentiment
File numbers found in text: 333-285098
Letter
February 25, 2025 Richard Anthony Cunningham Chief Executive Officer Anebulo Pharmaceuticals, Inc. 1017 Ranch Road 620 South, Suite 107 Lakeway, TX 78734 Re:Anebulo Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed February 20, 2025 File No. 333-285098 Dear Richard Anthony Cunningham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Leslie Marlow, Esq.
Show Raw Text
February 25, 2025
Richard Anthony Cunningham
Chief Executive Officer
Anebulo Pharmaceuticals, Inc.
1017 Ranch Road 620 South, Suite 107
Lakeway, TX 78734
Re:Anebulo Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed February 20, 2025
File No. 333-285098
Dear Richard Anthony Cunningham:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Leslie Marlow, Esq.